DUBLIN–(BUSINESS WIRE)–The “Gastric Cancer – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering.
This Gastric Cancer – Pipeline Insight, 2021 provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Gastric Cancer pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Gastric Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Gastric Cancer.
Gastric Cancer Emerging Drugs Chapters
This segment of the Gastric Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Gastric Cancer Emerging Drugs
IBI308: Innovent Biologics
IBI308 is a fully human monoclonal antibody that blocking programmed death protein-1. Innovent holds the global intellectual property rights of IBI308. Currently IBI308 has been approved for marketing by the NMPA. Acting as an immune checkpoint inhibitor by targeting PD-1, IBI308 boosts the immune response against tumor cells and inhibits the immune escape of tumor cells. Currently, it is in Phase III stage of clinical trial evaluation to treat gastric cancer.
HLX10: Henlix Biotech
It is a recombinant Humanised Anti-PD-1 Monoclonal Antibody Injection independently researched and developed by Henlius, is for the treatment of various solid tumors and can be applied in combination with other products for immuno-oncology therapy. Currently, it is in Phase III stage of clinical trial evaluation to treat gastric cancer.
Pamiparib: BeiGene
It is an investigational small molecule inhibitor of the PARP1 and PARP2 enzymes that is being evaluated as a potential monotherapy and in combination with other therapies to treat various solid tumors. Pamiparib’s early compound name was BGB-290. Currently, it is in Phase II stage of clinical trial evaluation to treat gastric cancer.
Major Players in Gastric Cancer
There are approx. 100+ key companies which are developing the therapies for Gastric Cancer. The companies which have their Gastric Cancer drug candidates in the most advanced stage, i.e. phase III include, Innovent Biologics.
Gastric Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Gastric Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Gastric Cancer drugs.
Key Questions Answered
- How many companies are developing Gastric Cancer drugs?
- How many Gastric Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Gastric Cancer?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Gastric Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Gastric Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Innovent Biologics
- Henlix Biotech
- BeiGene
- Hanmi Pharmaceutical Company Limited
- Hutchison Medipharma Limited
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Russian Pharmaceutical Technologies
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Idience
- AnewPharma
- MedPacto, Inc.
- Five Prime Therapeutics, Inc.
- Genentech
- Jiangsu Alphamab Biopharmaceuticals Co., Ltd
- Cellid Co., Ltd.
- Nanjing Legend Biotech Co.
- Eisai
- Jiangsu Hengrui Medicine Co.
- SYZ Cell Therapy Co.
- LintonPharm Co.,Ltd.
- Macrogenics
- OncoTherapy Science
- Avid Bioservices
- Taizhou EOC Pharma Co., Ltd.
- Bristol-Myers Squibb
- Carsgen Therapeutics, Ltd.
- Chengdu Kanghong Biotech Co., Ltd.
- Ganymed Pharmaceuticals
- Merck Sharp & Dohme Corp.
- NextCure, Inc.
- AstraZeneca
- Pfizer
- Pieris Pharmaceuticals, Inc.
- Ambrx, Inc.
- Merus N.V.
- GeneQuantum Healthcare (Suzhou) Co., Ltd.
- Highlight Therapeutics
- Qilu Pharmaceutical Co., Ltd.
- Green Cross Corporation
- Imugene Limited
- Vedanta Biosciences, Inc.
- Acepodia Biotech Inc.
- Keymed Biosciences Co.Ltd
- Bold Therapeutics, Inc.
- Regeneron Pharmaceuticals
- Celon Pharma SA
- Inhibrx, Inc.
- HiberCell, Inc.
- Treos Bio
Key Products
- IBI308
- HLX10
- Pamiparib
- FLX475
- Volitinib
- IBI-310
- Anlotinib
- Alofanib
- DP303c
- IDX-1197
- HLX22
- CM082
- TEW-7197
- Bemarituzumab
- Atezolizumab
- KN026
- BVAC-B
- LCAR-C18S
- Lenvatinib
- SHR6390
- Camrelizumab
- MASCT-I
- Catumaxomab
- INCMGA00012
- OTSGC-A24
- Bavituximab
- Telatinib
- BMS-986213
- AB011
- KH903
- Zolbetuximab
- Epacadostat
- NC410
- Durvalumab
- Crizotinib
- PRS-343
- ARX788
- MCLA-129
- GQ1001
- BO-112
- QL1604
- GC1118
- IMU-131
- VE800
- ACE1702
- CMG901
- BOLD-100
- 89Zr-DFO-REGN3504
- CPL304110
- INBRX-106
- HC-5404-FU
- PolyPEPI 1311
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/8417xj
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900